CTOs on the Move

Custom Spine Inc

www.customspine.com

 
Custom Spine Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Parsippany, NJ. To find more information about Custom Spine Inc, please visit www.customspine.com
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.customspine.com
  • 1140 Parsippany Blvd Ste 201
    Parsippany, NJ USA 07054-1887
  • Phone: 973.808.0019

Executives

Name Title Contact Details

Similar Companies

All Stat Home Healthcare

All Stat Home Health provides a full range of In-Home and Private Duty Home Health Care, catering specifically to the needs of the patient and family. We supply nursing personnel to Hospitals, Nursing Centers, Doctor's Offices and for private duty

Huron Medical Center

Huron Medical Center is committed to providing excellence in healthcare to our communities in a caring, compassionate manner. Huron Medical Center`s vision is to be the medical center for the communities served with continuous advancement of services offered.

Nephron Pharmaceuticals

Nephron Pharmaceuticals Corporation is a mid-sized company that manufactures generic respiratory medications. NPC sells to many classes of trade, including, but not limited to, hospitals, pharmacies, long term care facilities, home care companies and mail order pharmacies. These medications are used in the treatment of asthma and COPD.

KPR

KPR is a Granada Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.